1. Could you give us an overview of your company?

Novaerus is part of the WellAir company and owns a patented technology, NanoStrike, that is proven to irreversibly inactivate airborne pathogens at the DNA level in the sub-second timeframe. It does so without the use of harmful chemicals and with no maintenance.

Our mission is to restore health in the air we breathe without posing any risk to even the most vulnerable people.

2. How did your company first become involved in the IJCC?

Novaerus has been working closely with Enterprise Ireland and the broader Irish business community across the globe. We were connected with several members of the IJCC and were invited to attend a few of their events. After which, a formal invitation to join the chamber was graciously extended to Novaerus. We accepted and have since become active members of the chamber.

3. How has COVID-19 pandemic changed your business in a year?

COVID-19 has increased the awareness of the public to the need for an expanded set of infection control protocols, particularly looking into disinfecting the air. This has allowed us to engage medical institutions in a way that was not always available to us in the past. As a result, we’ve gained a significant amount of traction in multiple markets and sectors in a relatively short span of time.

At the same time, the pandemic has encouraged many other companies to throw their hats in to the mix. While this has broadened the options for end users—which no doubt will contribute to the continued improvement of products in the category—it has also introduced a new set of challenges both to the end customers and to ourselves. For instance, understanding the differences and levels of effectiveness of available technologies has become more challenging recently. This potential for confusion, in turn, requires us to be more precise in highlighting our advantages vs. competition and pointing to scientific evidence that provides proof for our claims.

4. What areas of growth do you see for your company (or sector) in the next 12 to 24 months?

The core of our business remains to be the medical sector. However, the risk of infection is present everywhere, so we are already seeing an increase in uptake for our products in non-medical sectors as well.

We expect this trend to continue as CoVid19 transitions from being treated as a pandemic to being accepted as endemic and part of the “new normal”.

5. You won Company of the Year Award of Ireland Japan Business Awards 2021. Could you give us your comment about it?

It is an honour to be recognized and singled out by the chamber. Every company in the IJCC has worked hard (and continues to work hard) to add value to its clients given the challenges in the last 24 months. To be chosen in this field of very good companies is a great achievement for us.